Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8.695 USD | +4.89% | +1.70% | -18.92% |
Sales 2024 * | 538K 734K | Sales 2025 * | 675K 921K | Capitalization | 24.54M 33.49M |
---|---|---|---|---|---|
Net income 2024 * | -37M -50.5M | Net income 2025 * | -48M -65.52M | EV / Sales 2024 * | 45.6 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 36.3 x |
P/E ratio 2024 * |
-0.78
x | P/E ratio 2025 * |
-0.98
x | Employees | 29 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.25% |
Latest transcript on Oncternal Therapeutics, Inc.
1 day | +4.89% | ||
1 week | +1.70% | ||
Current month | -3.39% | ||
1 month | -6.51% | ||
3 months | -12.88% | ||
6 months | +33.36% | ||
Current year | -18.92% |
Managers | Title | Age | Since |
---|---|---|---|
James Breitmeyer
FOU | Founder | 70 | 96-12-31 |
Richard Vincent
DFI | Director of Finance/CFO | 61 | 17-03-31 |
Salim Yazji
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-05-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Hale
FOU | Founder | 75 | 96-12-31 |
Dan Kisner
BRD | Director/Board Member | 77 | 19-06-06 |
Rosemary Mazanet
BRD | Director/Board Member | 67 | 21-01-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 8.695 | +4.89% | 1 790 |
24-04-26 | 8.29 | +0.48% | 1,441 |
24-04-25 | 8.25 | -3.45% | 6,862 |
24-04-24 | 8.545 | -2.51% | 1,600 |
24-04-23 | 8.765 | +2.51% | 955 |
Delayed Quote Nasdaq, April 29, 2024 at 12:58 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.92% | 24.54M | |
+2.64% | 42.75B | |
+47.70% | 41.61B | |
+12.13% | 41.34B | |
-8.83% | 26.59B | |
+7.59% | 25.49B | |
-22.58% | 18.12B | |
+30.71% | 12.24B | |
-1.77% | 11.76B | |
+9.40% | 11B |
- Stock Market
- Equities
- ONCT Stock